In the Research Letter titled “Use of Artificial Intelligence in Drug Development,”1 published May 31, 2024, 2 percentages in the Results section were given incorrectly. The percentage of drugs for which AI was used for a cancer indication should have appeared as 32% instead of 27%, and the number and percentage of drugs for which AI was used for a neurological indication should have appeared as n = 46 and 28% instead of 24%. This article has been corrected.1
Reference
- 1.Druedahl LC, Price WN II, Minssen T, Sarpatwari A. Use of artificial intelligence in drug development. JAMA Netw Open. 2024;7(5):e2414139. doi: 10.1001/jamanetworkopen.2024.14139 [DOI] [PMC free article] [PubMed] [Google Scholar]